- Home
- TDF vs EYPT Comparison
TDF vs EYPT Comparison
Compare TDF & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | EYPT |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | 214 |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.8M | 273.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | TDF | EYPT |
|---|---|---|
| Price | $9.40 | $3.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $25.91 |
| AVG Volume (30 Days) | 46.2K | ★ 3.2M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $943.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $3.05 |
| 52 Week High | $12.20 | $19.11 |
Technical Indicators
Market Signals| Indicator | TDF | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 22.65 | 32.91 |
| Support Level | N/A | N/A |
| Resistance Level | $11.17 | $14.72 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | -0.03 | 0.18 |
| Stochastic Oscillator | 5.22 | 26.18 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.